

FOR IMMEDIATE RELEASE

**BIOLEX THERAPEUTICS FEATURED AT NEXT GENERATION ANTIBODY
PANEL AT BIO CEO & INVESTOR CONFERENCE**

PITTSBORO, NORTH CAROLINA, February 13, 2007 - Biolex Therapeutics today announced that its technology for optimizing monoclonal antibodies will be featured at the "Next Generation Antibodies and Antibody Technologies" session at the 9th Annual BIO CEO & Investor Conference. David Spencer, Ph.D., Biolex's Chief Operating Officer and Senior Vice President, Research and Development, will highlight the ability of the Company's LEX SystemSM to increase the efficacy and potency of monoclonal antibodies. The antibody session will take place at 9:00 a.m. EST on Wednesday, February 14th at the Waldorf Astoria in New York City.

Monoclonal antibodies comprise the fastest growing class of protein therapeutics and are currently being used and developed primarily to treat cancers, autoimmune diseases, infectious diseases and inflammatory diseases. Recently, Biolex announced results published in *Nature Biotechnology* demonstrating the ability of its proprietary LEX System to produce monoclonal antibodies that have enhanced potency and efficacy. The publication also describes the LEX System's ability to produce antibodies with homogeneous glycosylation structures, an additional major advantage of the LEX System compared to expression systems commonly used today, and key to reducing production risks, regulatory risks and costs.

"Biolex has successfully produced antibodies with optimized glycosylation in multiple protein candidates held by our corporate partners and in one of our own product candidates," said David Spencer, Ph.D., Biolex Chief Operating Officer and Senior Vice President, Research and Development. "The ability of the LEX System to produce antibodies with greater functionality is obviously a major benefit. Moreover, controlling glycosylation and achieving consistent production throughout scale-up resolves a significant challenge facing the biopharmaceutical industry."

About Biolex Therapeutics

Biolex Therapeutics is developing and commercializing therapeutic proteins based on its proprietary LEX SystemSM, an expression system that enables the production, development and commercialization of hard-to-make proteins and the optimization of monoclonal antibodies. The Company is developing a proprietary pipeline of products that rely upon known mechanisms of action to provide a reduced risk profile while targeting large, proven pharmaceutical markets. Biolex's lead candidate, LocteronTM, is being developed as a best-

- more -





in-class controlled-release interferon alfa for the treatment of hepatitis C. The Company's second product candidate, BLX-155, is a direct-acting thrombolytic, designed to break up clots in certain diseases such as acute peripheral arterial disease, catheter occlusion and deep vein thrombosis. In addition, the unique capabilities of the LEX System have led to collaborations with Centocor, Medarex and other leading pharmaceutical/biotech companies. Biolex is a venture-capital-backed company located in the Research Triangle region of North Carolina, United States. For additional information, please visit Biolex's web site at www.biolex.com.

###

Contacts:

Media: Michelle Linn, Linnden Communications, 774-696-3803, linnmich@comcast.net.

Investors: Dale Sander, Chief Financial Officer, 858-663-6993, dsander@biolex.com



158 Credle Street
Pittsboro, NC 27312
www.biolex.com

tel 919.542.9901
fax 919.542.9910